EarningsQ1 2026 Earnings Report
MX:TEM Q1 2026 EPS Results
Actual EPS-$2.25
Consensus EPS-$3.47
Beat/MissBeat by +$1.21
One Year Ago EPS-$4.16
MX:TEM Q1 2026 Revenue Results
Actual Revenue$6.03B
Expected Revenue$5.99B
Beat/MissBeat by +$46.40M
YoY Revenue Growth+36.12%
Earnings Announcement Details
QuarterQ1 2026
Date05/05/2026
TimeAfter Close
Conference CallTuesday, May 5, 2026
MX:TEM Upcoming Earnings
Tempus AI, Inc. Class A's next earnings date is estimated for November 10, 2026, based on past reporting schedules.
Q1 2026 Earnings Call Audio
MX:TEM Q1 2026 Earnings Call
0:00 / 0:00
Q1 2026 Earnings Slide Deck
Q1 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong topline momentum and durable demand in both diagnostics and data/applications: revenue growth (~36% YoY), robust Data & Insights growth (40.5% YoY; Insights >44%), expansion of large pharma collaborations (Merck, Gilead), rising bookings/TCV and an upgraded full-year revenue guide to $1.59B–$1.60B with adjusted EBITDA targeted at ~$65M. Key risks and near-term headwinds include Q1 cash-flow timing effects, slower hereditary volumes early in the year, MRD reimbursement and scaling constraints, and some regulatory timing uncertainty. Overall the positives (strong growth, expanding high-value contracts, improving EBITDA trajectory and sizable data assets) outweigh the transitory operational and reimbursement challenges.Company Guidance
Strong Overall Revenue Growth and Upgraded Guidance
Total revenue of $348.1M, up a little over 36% year-over-year. Company raised full-year revenue guidance to $1.59B–$1.60B and expects adjusted EBITDA of about $65M for FY2026.
Diagnostic Segment Strength, Especially Oncology
Diagnostic revenue $261.1M, representing ~35% YoY growth driven by oncology. Oncology unit growth ~28%; solid tumor and liquid biopsy performing well; MRD volume showing strong percentage growth (see MRD highlight). Hereditary testing slowed vs prior-year extreme growth but management expects a return to mid-teens growth in H2.
Data & Applications (Insights) Surge
Data applications revenue $87M, up 40.5% YoY. Insights product grew over 44%. Third straight quarter of bookings north of $100M; total contract value (TCV) increased in Q1 and management had previously noted ~$350M of TCV related to 2026, providing visibility into 2026 revenue.
Large Strategic Pharma Collaborations and Pipeline Momentum
Added large strategic collaborations in Q1 including Merck (very large) and an expansion with Gilead, and continues to add top pharma names. Management reports a robust pipeline and multiple $100M+ multi-year de-identified data licensing/modeling agreements.
Extensive Data Assets and Model-Building Capabilities
Proprietary database exceeds 500 petabytes, connected to analytics and GPU-enabled model-building platform; customers increasingly building proprietary models with Tempus data (foundation models and smaller models).
Improving Profitability Trend
Adjusted EBITDA was about a $3M loss in Q1 but management reported ~ $13M YoY improvement in Q1 and expects continued quarter-over-quarter EBITDA improvement, with a full-year adjusted EBITDA target of ~$65M.
MRD Traction (High Percentage Growth Off Small Base)
MRD volume described as performing very well; management cited MRD assay growth of ~500% YoY (from a small base of ~6.5k tests), indicating early strong uptake and meaningful longer-term upside if reimbursement and scaling occur.
MX:TEM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed